Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2017
Q1
Sell
-17,100
Closed -$8K 292
2016
Q4
$8K Sell
17,100
-11,200
-40% -$3.32M 0.01% 210
2016
Q3
$678K Sell
28,300
-8,900
-24% -$2.64M 0.54% 44
2016
Q2
$118K Buy
37,200
+5,000
+16% +$1.32M 0.1% 133
2016
Q1
$306K Buy
32,200
+14,900
+86% +$3.94M 0.32% 60
2015
Q4
$148K Buy
+17,300
New +$4.97M 0.11% 118

Other funds holding BIIB

FT Options's BIIB Position: Q1 2017 in Review

FT Options sold out of Biogen (BIIB) in Q1 2017, closing a stake of 3,191 shares — an estimated $905K sold.

FT Options first reported a position in BIIB in Q4 2015 and held it in 4 quarters. The position peaked at $3.54M in Q2 2016. 1,019 funds tracked by Wall St. Rank hold BIIB as of Q1 2017.

  • FT Options reported no remaining Biogen position as of Q1 2017 after selling out during the quarter.
  • FT Options sold 3,191 Biogen shares in Q1 2017, an estimated $905K.
  • FT Options first reported a position in Biogen in Q4 2015 and held it in 4 quarters.
  • FT Options's Biogen position peaked at $3.54M in Q2 2016.
  • 1,019 funds tracked by Wall St. Rank held Biogen as of Q1 2017.

Based on FT Options's 13F filing for Q1 2017, filed 12 May 2017.